RedHill Biopharma’s Talicia Receives Approval in the United Arab Emirates for the Treatment of H. Pylori
Shots:
- RedHill's partner Gaelan Medical, part of the Ghassan Aboud Group (GAG) receive marketing approval from the UAE Ministry of Health for Talicia (omeprazole magnesium, amoxicillin & rifabutin)
- The P-III study results showed that patients treated with Talicia achieved 84% eradication of H. pylori inf. in the ITT group vs 58% in active comparator arm, minimal to zero resistance to rifabutin was detected, patients had response rates of 90.3% vs 64.7%
- Talicia, a novel rifabutin-containing all-in-one oral capsule designed to treat H. pylori & was approved in the US for H. pylori inf. in adults along with eligible for 8yrs. of US market exclusivity under QIDP designation
Ref: PR Newswire | Image: RedHill
Related News:- RedHill Biopharma's Talicia Received the US FDA's Approval for H. pylori in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
